https://scholars.lib.ntu.edu.tw/handle/123456789/549444
Title: | AUY922 effectively targets against activated B cell subtype of diffuse large B-cell lymphoma and low-grade lymphoma cells harboring genetic alteration-associated nuclear factor-B activation | Authors: | Tsai H.-J. Shih N.-Y. SUNG-HSIN KUO ANN-LII CHENG Lin H.-Y. Chen T.-Y. Chang K.-C. Lin S.-F. Chang J.S. Chen L.-T. |
Issue Date: | 2015 | Publisher: | Taylor and Francis Ltd | Journal Volume: | 56 | Journal Issue: | 9 | Start page/Pages: | 2674-2682 | Source: | Leukemia and Lymphoma | Abstract: | Recurrent genetic alterations that are frequently observed in some low-grade lymphomas, such as activated B cell subtype of diffuse large B-cell lymphoma (ABC-DLBCL) and mucosa-associated lymphoid tissue type lymphoma (MALT lymphoma) are usually associated with nuclear factor-B (NF-B) activation and confer resistance to therapy. In this study, we investigated the therapeutic efficacy and molecular mechanisms of AUY922, a novel Hsp90 inhibitor, in representative cell lines OCI-Ly3 (ABC-DLBCL) and MA-1 (a low-grade lymphoma cell line with t(14;18)/IgH-MALT1translocation) to explore its potential use in the treatment of refractory B-cell lymphoma. Our results showed that AUY922 effectively induced growth inhibition and apoptosis of OCI-Ly3 and MA-1 cells, which were accompanied by down-regulation of the expression levels of NF-B and Bcl-2 family proteins, as well as molecules of multiple signaling pathways involving cell proliferation, growth and survival. The growth inhibitory effect of AUY922 was further confirmed in a mouse xenograft model. These findings indicate the potential use of AUY922 in B cell lymphomas. ? 2015 Informa UK, Ltd. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84946052219&doi=10.3109%2f10428194.2014.995647&partnerID=40&md5=8826aead274210da19f43b0ae1725731 https://scholars.lib.ntu.edu.tw/handle/123456789/549444 |
ISSN: | 1042-8194 | DOI: | 10.3109/10428194.2014.995647 | SDG/Keyword: | caspase 3; caspase 9; immunoglobulin enhancer binding protein; luminespib; protein bcl 2; 5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide; antineoplastic agent; caspase 3; caspase 9; heat shock protein 90; immunoglobulin enhancer binding protein; isoxazole derivative; resorcinol derivative; activated B cell subtype of diffuse large B cell lymphoma; activated B cell subtype of diffuse large B cell lymphoma; animal experiment; animal model; apoptosis; Article; B lymphocyte; cancer inhibition; cell activation; cell cycle arrest; cell growth; cell proliferation; cell survival; controlled study; down regulation; drug efficacy; enzyme activation; growth inhibition; large cell lymphoma; male; marginal zone lymphoma; mouse; nonhuman; priority journal; protein expression; animal; antagonists and inhibitors; B lymphocyte; cancer grading; cell cycle checkpoint; chromosome 14; chromosome 18; chromosome aberration; disease model; drug effects; drug screening; gene translocation; genetics; human; Lymphoma, Large B-Cell, Diffuse; metabolism; mitochondrion; pathology; signal transduction; tumor cell line; tumor volume; Animals; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Caspase 3; Caspase 9; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromosome Aberrations; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 18; Disease Models, Animal; Down-Regulation; Enzyme Activation; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lymphoma, Large B-Cell, Diffuse; Male; Mice; Mitochondria; Neoplasm Grading; NF-kappa B; Resorcinols; Signal Transduction; Translocation, Genetic; Tumor Burden; Xenograft Model Antitumor Assays |
Appears in Collections: | 腫瘤醫學研究所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.